21^st Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Area of Science:

• Regulatory Science
• Health Policy
• Patient Advocacy

Background:

• The United States Food and Drug Administration (FDA) operates under a perpetual tension between facilitating access and innovation while safeguarding public health.
• Legislative changes over the past century have continually reshaped the FDA's regulatory authority for drugs, biologics, and medical devices.
• The 21st Century Cures Act marked a significant reframing of the FDA's directive, emphasizing the inclusion of patient perspectives.

Purpose of the Study:

• To explore recent advancements in patient-focused product development initiatives within the FDA.
• To analyze the growing influence of patients and patient advocacy groups on FDA decision-making processes.
• To characterize the current era of patient involvement in pharmaceutical and device regulation as '21st century citizen pharma.'

Main Methods:

• Review of recent FDA initiatives and legislative impacts.
• Analysis of the role of patient perspectives in regulatory frameworks.
• Examination of the influence of patient advocacy groups on agency decision-making.

Main Results:

• The FDA is actively developing patient-focused product development strategies.
• Patient and patient advocacy group input is becoming more integral to FDA regulatory processes.
• The legislative landscape, particularly the 21st Century Cures Act, supports this increased patient engagement.

Conclusions:

• The FDA's regulatory paradigm is evolving to incorporate patient voices more significantly.
• The '21st century citizen pharma' era signifies a fundamental shift towards patient-centered drug and device regulation.
• Continued patient engagement is crucial for balancing innovation with public health and safety.